ClinicalTrials.gg
Not yet recruitingNCT07944391Updated Nov 18, 2026

Acceptance and Commitment Therapy for Mesh Injury: A HSCED Series

An interventional study of Acceptance and Commitment Therapy in Acceptance and Commitment Therapy, Psychological Distress and Stress Urinary Incontinence in Women, sponsored by University of Lincoln. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Lincoln · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The Patient Safety Commissioner estimates that at least 10,000 women in England have experienced significant harm resulting from vaginal mesh implants. Adverse effects resulting in psychological distress and reduced quality of life have been reported. The purpose of the study is to explore the efficacy of Acceptance and Commitment Therapy (ACT) for women with mesh injury experiencing psychological distress.

The study will use a Hermeneutic Single-Case Efficacy Design to answer the primary and secondary objectives.

Primary objective: To investigate whether ACT is an effective therapeutic intervention for women experiencing psychological distress due to mesh injury.

Secondary objectives: To determine whether there are any meaningful changes throughout the ACT intervention; whether these changes can be attributed to the ACT intervention and what factors contribute to the changes.

Participants will undergo a ten-session ACT intervention and follow-up session. A qualitative interview will be carried out to explore the change experience.

Read the detailed description

NICE guidelines recognise the physical and psychological impact of mesh complications and recommends that psychological and psychosexual support is offered to women affected. Despite this, a therapeutic intervention for mesh complications has not yet been explored. Acceptance and Commitment Therapy (ACT) as been empirically supported for its use with populations with long term health conditions.

The study will use a hermeneutic single-case efficacy design and evaluate the process of change during the intervention. Following the ACT intervention, rich case records for each participant will be created using quantitative and qualitative data; this data will consist of demographic data, outcome measures and therapy material. The rich case records will be cross-referenced and amalgamated into an "affirmative" brief that presents evidence that the change can be attributed to the therapeutic intervention. The rich case record will also be analysed for indirect evidence to develop a "skeptic" brief, a brief presenting an alternative explanation for the therapeutic change. Both analyses will be evaluated through a presentation of both briefs, a rebuttal of the opposing brief and a summary narrative . The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome.

02

Conditions studied

  • Acceptance and Commitment Therapy
  • Psychological Distress
  • Stress Urinary Incontinence in Women
  • Pelvic Organ Prolapse (POP)
  • Surgery Complications

Browse trials for

Keywords

  • Psychological distress
  • HSCED
  • Pelvic mesh complication
  • Pelvic mesh
  • ACT
03

In context

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

This study's planned enrollment of 6 is below the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.

Browse Pelvic Organ Prolapse studies →

Lead sponsor

University of Lincoln is the lead sponsor of 27 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Woman aged 18 or over.

  • Registered with a UK GP.
  • Currently under the care of or recently discharged from Nottingham or Manchester Complex Mesh Centres or have contacted their GP about mesh complications.
  • Has had surgery for Stress Urinary Incontinence (SUI) and/or Pelvic Organ Prolapse (POP) and has or have had implanted polypropylene mesh causing complications.
  • Experiencing self-reported psychological distress.
  • Able to communicate in English.
  • Has access to a device with internet access.
  • Willing and able to provide for participation in the study.
  • Willing to engage in psychological therapy.

Exclusion criteria

Exclusion Criteria:

  • ACT intervention in the past twelve months due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Currently engaging in psychological therapy due to the potential impact on the efficacy of the therapeutic intervention and to reduce cofounding variables.
  • Have insufficient command of the English language due to resources and potential impact of an interpreter on mechanism of change.
  • Significant cognitive impairment.
  • Current suicidal ideation for ethical and safety reasons.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Acceptance and Commitment Therapy

    Participants will receive a ten-session Acceptance and Commitment Therapy (ACT) intervention

    Behavioral: Acceptance and Commitment Therapy

Interventions

  • BehavioralAcceptance and Commitment Therapy

    Acceptance and commitment therapy (ACT) is a "third wave" Cognitive Behavioural Therapy that focuses on increasing psychological flexibility and acceptance of difficult experiences by undertaking value-drive actions despite psychological suffering. Psychological flexibility is developed and expanded through six core processes: acceptance, defusion, present moment awareness, self-as-context, values and committed action. Adherence to a strict protocol is not mandated for an ACT intervention; the study will be informed by an adapted ACT intervention for chronic pain (Scott et al., 2018). The intervention will reflect the heterogenous nature of mesh injury. The intervention will consist of ten individual weekly sessions lasting up to 60 minutes.

06

What researchers measure

Primary outcomes

  1. Hermeneutic Single-Case Efficacy Design - adjudication

    The adjudication process will be overseen by three independent judges who will evaluate the rich case records and briefs to provide an outcome ; whether there has been a change during the therapeutic intervention and whether the therapeutic intervention was a key influence on this outcome (Elliott et al., 2009).

    Time frame: Through study completion, an average of 9 months.

  2. Psychological distress assessed using the Clinical Outcomes in Route Evaluation 10 (CORE-10; Barkham et al., 2013)

    10-item measure designed to measure common presentations of psychological distress. The minimum value is 0 and the maximum value is 40. A higher score indicates severe distress.

    Time frame: From baseline to the end of treatment, up to 16 weeks.

Secondary outcomes

  1. Mesh symptoms impact on quality of life assessed using the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol; Kelleher et al., 1997)

    20-item measure designed to measure the physical, emotional, social, and practical impact of urinary symptoms. Measure adapted to assess "mesh problem" instead of "urinary problem" (Brown, 2020). The minimum value is 0 and the maximum value is 76. A higher score indicates greater impact on quality of life.

    Time frame: From baseline to the end of treatment, up to 16 weeks.

  2. Psychological flexibility assessed using the Comprehensive assessment of Acceptance and Commitment Therapy Processes (CompACT-10; Golijani-Moghaddam et al., 2023)

    10-item short-form version of the Comprehensive Assessment of Acceptance and Commitment Therapy Processes (CompACT), designed to measure psychological flexibility and its core sub-processes. The minimum value is 0 and the maximum value is 60. A higher score indicates greater level of psychological flexibility.

    Time frame: From baseline to the end of treatment, up to 16 weeks.

  3. Therapeutic alliance assessed using the Session Rating Scale (SRS; Duncan et al., 2003)

    4-item measure designed to measure the quality of the therapeutic alliance. The minimum value is 0 and the maximum value is 40. A higher score indicates greater therapeutic alliance.

    Time frame: Weekly during the therapy intervention, up to 10 weeks.

  4. Client's perception of therapy sessions assessed using the Helpful Aspects of Therapy (HAT; Llewelyn, 1988)

    A measure designed to identify specific events that participants found most helpful during the therapy session. The minimum value is 1 and the maximum value is 9 for each scale. A higher score indicates greater helpful impact.

    Time frame: Weekly during the therapy intervention, up to 10 weeks.

  5. Change in client's goals assessed using the Personal Questionnaire (PQ; Elliott et al., 1999)

    A measure personalised to the participant, identifying problems that the participant would like to work on in therapy. The minimum value is 7 and the maximum value is 91 for each scale. A higher score indicates greater progress towards goals/problem identified at the start of therapy.

    Time frame: Weekly during the therapy intervention, up to 10 weeks.

  6. Adherence to ACT processes measured using the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM; O'Neill et al., 2019)

    A measure of therapist fidelity in delivering Acceptance and Commitment Therapy. The minimum value is 0 and the maximum value is 36 for ACT consistent and ACT inconsistent subscales. A higher score for the ACT consistent subscale indicates adherence to ACT processes.

    Time frame: During the therapy intervention for up to 10 weeks.

  7. Client's perception of therapy intervention and change processes assessed using the Client Change Interview (Elliott et al., 2001)

    A semi-structured interview to explore the mechanism of change.

    Time frame: Within two weeks of end of therapy intervention, at 12 weeks.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • O'Neill, L., Latchford, G., McCracken, L. M., & Graham, C. D. (2019). The development of the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM): A Delphi study and field test. Journal of Contextual Behavioral Science, 14, 111-118. https://doi.org/10.1016/j.jcbs.2019.08.008
  • Elliott, R., Mack, C., & Shapiro, D. A. (1999). Simplified Personal Questionnaire procedure manual. University of Toledo, Department of Psychology, Toledo, Ohio, USA.
  • Llewelyn SP. Psychological therapy as viewed by clients and therapists. Br J Clin Psychol. 1988 Sep;27(3):223-37. doi: 10.1111/j.2044-8260.1988.tb00779.x. PubMed 3191302 ↗
  • Duncan, B., Miller, S., Sparks, J., Claud, D.A., Reynolds, L., Brown, J., & Johnson, LD. (2003). The Session Rating Scale: Preliminary Psychometric Properties of a "Working" Alliance Measure. Journal of Brief Therapy. 3. 3-12.
  • Golijani-Moghaddam, N., Morris, J. L., Bayliss, K., & Dawson, D. L. (2023). The CompACT-10: development and validity of a comprehensive assessment of acceptance an commitment therapy processes short-form in representative UK samples. Journal of Contextual Behavioral Science, 29, 59-66. doi: 10.1016/j.jcbs.2023.06.003.
  • Brown JL. The experiences of seven women living with pelvic surgical mesh complications. Int Urogynecol J. 2020 Apr;31(4):823-829. doi: 10.1007/s00192-019-04155-w. Epub 2019 Dec 4. PubMed 31802166 ↗
  • Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997 Dec;104(12):1374-9. doi: 10.1111/j.1471-0528.1997.tb11006.x. PubMed 9422015 ↗
  • Barkham, M., Bewick, B., Mullin, T., Gilbody, S., Connell, J., Cahill, J., Mellor-Clark, J., Richards, D., Unsworth, G., & Evans, C. (2013). The CORE-10: A short measure of psychological distress for routine use in the psychological therapies. Counselling & Psychotherapy Research, 13(1), 3-13. https://doi.org/10.1080/14733145.2012.729069
  • Scott W, Chilcot J, Guildford B, Daly-Eichenhardt A, McCracken LM. Feasibility randomized-controlled trial of online Acceptance and Commitment Therapy for patients with complex chronic pain in the United Kingdom. Eur J Pain. 2018 Apr 28. doi: 10.1002/ejp.1236. Online ahead of print. PubMed 29704880 ↗
  • Elliott R, Partyka R, Alperin R, Dobrenski R, Wagner J, Messer SB, Watson JC, Castonguay LG. An adjudicated hermeneutic single-case efficacy design study of experiential therapy for panic/phobia. Psychother Res. 2009 Jul;19(4-5):543-57. doi: 10.1080/10503300902905947. PubMed 20183406 ↗

Individual participant data

Plan to share: No — The results of the research study will be submitted in partial fulfilment of doctoral thesis in Clinical Psychology. A journal manuscript will be submitted to a peer-reviewed journal and any data submitted will be anonymised. Any published outputs will contain a data availability statement linked to the repository. The full dataset and any special category data will not be publicly available due to participant privacy.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 8 months is below that.

Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944391
Lead sponsor
University of Lincoln
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Jessica Oshodin, MSc, BSc
Contact
29629594@students.lincoln.ac.uk
01522 882000
Danielle De Boos, ClinPsyD
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion